Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell of lymphatic vessel | 13 studies | 24% ± 7% | |
mast cell | 9 studies | 31% ± 10% | |
club cell | 7 studies | 27% ± 11% | |
respiratory goblet cell | 7 studies | 35% ± 22% | |
basal cell | 6 studies | 36% ± 14% | |
secretory cell | 5 studies | 32% ± 16% | |
glutamatergic neuron | 5 studies | 20% ± 5% | |
ciliated cell | 4 studies | 34% ± 13% | |
epithelial cell | 3 studies | 30% ± 11% | |
Mueller cell | 3 studies | 18% ± 1% | |
GABAergic neuron | 3 studies | 26% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 4 studies | 29% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 98% | 315.64 | 944 / 966 | 96% | 8.24 | 508 / 527 |
stomach | 98% | 412.70 | 353 / 359 | 95% | 9.79 | 271 / 286 |
kidney | 100% | 1333.06 | 89 / 89 | 92% | 16.64 | 828 / 901 |
bladder | 95% | 1015.10 | 20 / 21 | 93% | 11.84 | 467 / 504 |
esophagus | 98% | 917.56 | 1420 / 1445 | 90% | 10.80 | 164 / 183 |
lung | 98% | 437.97 | 567 / 578 | 89% | 10.03 | 1030 / 1155 |
uterus | 100% | 798.04 | 170 / 170 | 79% | 9.27 | 362 / 459 |
brain | 95% | 941.94 | 2499 / 2642 | 80% | 9.56 | 565 / 705 |
prostate | 100% | 489.02 | 245 / 245 | 75% | 5.40 | 375 / 502 |
ovary | 100% | 6662.34 | 180 / 180 | 68% | 3.35 | 293 / 430 |
adrenal gland | 100% | 392.14 | 257 / 258 | 68% | 7.94 | 156 / 230 |
breast | 95% | 435.80 | 437 / 459 | 50% | 1.88 | 558 / 1118 |
thymus | 97% | 385.53 | 631 / 653 | 40% | 1.86 | 243 / 605 |
pancreas | 23% | 39.75 | 75 / 328 | 96% | 22.49 | 170 / 178 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.26 | 1 / 1 |
spleen | 100% | 435.21 | 240 / 241 | 0% | 0 | 0 / 0 |
adipose | 93% | 368.81 | 1116 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 82% | 8.35 | 37 / 45 |
heart | 76% | 210.30 | 656 / 861 | 0% | 0 | 0 / 0 |
skin | 32% | 53.77 | 584 / 1809 | 43% | 2.36 | 205 / 472 |
blood vessel | 67% | 157.05 | 890 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 1.57 | 8 / 29 |
liver | 8% | 13.97 | 18 / 226 | 15% | 1.83 | 60 / 406 |
peripheral blood | 18% | 71.68 | 167 / 929 | 0% | 0 | 0 / 0 |
muscle | 15% | 19.41 | 121 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.04 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0015015 | Biological process | heparan sulfate proteoglycan biosynthetic process, enzymatic modification |
GO_0006024 | Biological process | glycosaminoglycan biosynthetic process |
GO_0005796 | Cellular component | Golgi lumen |
GO_0008467 | Molecular function | [heparan sulfate]-glucosamine 3-sulfotransferase 1 activity |
GO_0008146 | Molecular function | sulfotransferase activity |
Gene name | HS3ST1 |
Protein name | Heparan sulfate-glucosamine 3-sulfotransferase 1 Heparan sulfate glucosamine 3-O-sulfotransferase 1 (EC 2.8.2.23) (Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 1) (3-OST-1) (Heparan sulfate 3-O-sulfotransferase 1) (h3-OST-1) HS3ST1 protein |
Synonyms | 3OST1 3OST |
Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to position 3 of glucosamine residues in heparan . Catalyzes the rate limiting step in the biosynthesis of heparan sulfate (HSact) . This modification is a crucial step in the biosynthesis of anticoagulant heparan sulfate as it completes the structure of the antithrombin pentasaccharide binding site . . |
Accessions | E9PDE3 ENST00000002596.6 O14792 ENST00000514690.5 ENST00000510712.1 Q05CH3 |